Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas.
about
Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1.From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas.Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions.Pivotal molecules of MHC I pathway in human primary hepatocellular carcinomaIn vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunityInterleukin-21 Drives Proliferation and Differentiation of Porcine Memory B Cells into Antibody Secreting Cells.The role of B7 family molecules in hematologic malignancyEmerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion.Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity.Targeting Immune Checkpoints in Hematologic Malignancies.CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma.The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen-presenting cells.450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments.PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.Identification of a circulating soluble form of CD80: levels in patients with hematological malignanciesEpidermal keratinocytes do not activate peripheral T-cells: interleukin-10 as a possible regulator
P2860
Q30425516-279C91D6-8A40-48CD-A892-E18D23534B19Q33929813-36D6D0B6-E0C1-45CC-9EB2-D0C4D5C57F56Q34480019-0A6515B1-CB94-42BA-AAA5-7C1BDE60520AQ35045664-7DF8F178-0839-4352-9A8E-B1C94D35FAC4Q35848586-EE5D6384-659B-46B9-8A59-6C52E2BB9A98Q36261556-9E530883-5732-4CA5-976F-1017B53CD3F2Q36584814-09CB8FDA-020C-408A-9113-ED2CA232C967Q38068494-234073C0-2495-4169-AAFE-E2E1823C3895Q38344066-1F97B691-7660-47FB-AC8A-982076132E90Q38714687-A837BCC7-B0BC-42FC-84D3-72F95943D0CAQ38810148-BAC49EB5-17ED-4E99-AF2B-BADEFEC37DA0Q38963420-B3ECA63E-D8B4-43EB-B1D4-2D0E06E3145FQ39444397-97047832-2390-44AD-861B-0079FF5FDFA8Q39796169-AD194336-891F-43E7-9F13-8172A3DFB38DQ43939577-2521BFE8-8ACF-4A61-8D3F-44FF477B21F3Q47424027-9DB5B7F6-2B6A-468B-8C87-06E2470407E3Q56903301-6E9D45A0-DC67-4829-97B3-D9925B9D02BBQ57058827-A849C813-FE63-4BAD-AD25-6F99A80E5403
P2860
Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Functional expression of CD80 ...... from non-Hodgkin's lymphomas.
@en
type
label
Functional expression of CD80 ...... from non-Hodgkin's lymphomas.
@en
prefLabel
Functional expression of CD80 ...... from non-Hodgkin's lymphomas.
@en
P2093
P1476
Functional expression of CD80 ...... from non-Hodgkin's lymphomas.
@en
P2093
Chaperot L
P304
P356
10.1016/S0301-472X(98)00059-9
P577
1999-03-01T00:00:00Z